Visceral fat is not merely stored energy—it is a biologically active tissue that drives insulin resistance, cardiovascular disease, cognitive decline, and accelerated aging. Many individuals with normal weight harbor excess visceral fat. Identifying and reducing it early can dramatically improve metabolic health and long-term healthspan.

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly called fatty liver, is not a liver problem alone—it is a systemic marker of insulin resistance. Often silent for years, MASLD signals elevated cardiometabolic, cognitive, and longevity risk long before abnormal liver enzymes or diabetes appear.

Insulin resistance often develops years before diabetes, heart disease, or dementia are diagnosed. During this silent phase, metabolic dysfunction damages blood vessels, the brain, and cellular aging pathways. Understanding insulin resistance early allows for targeted intervention that can meaningfully reduce cardiovascular risk, cognitive decline, and accelerated biological aging.

Lactoferrin-rich colostrum occupies a unique niche at the intersection of mucosal immunity, systemic inflammatory control, and sleep regulation. By combining the broad matrix of colostrum with the targeted antiviral, antibacterial, and immunomodulatory activity of lactoferrin, these preparations can reduce the burden of upper respiratory infections, support resilient immune function, and modestly improve sleep quality in selected populations. As with any therapeutic nutrient,